• Archives of Pharmacal Research
• /
• v.21 no.6
• /
• pp.657-663
• /
• 1998

The enzyme responsible for the synthesis of nitric oxide (NO) from L-arginine in mammalian tissues is known as nitric oxide synthase (NOS) (EC.1.14.13.39). In the present study, the role of NO in the regulation of exocrine secretion was investigated in rat pancreatic acinar cells. Treatment of rat pancreatic acinar cells with cholecystokinin-octapeptide (CCK-OP) resulted in an increase in the arginine conversion to citrulline, the amount of $NO_X$, the release of amylase, and the level of CGMP. Especially, CCK-OP-stimulated increase of arginine to citrulline transformation, the amount of $NO_X$, and CGMP level were completely counteracted by the inhibitor of NOS, NG-monomethyl-L-arginine (MMA), by contrast, that of amylase release was partially reduced. Furthermore, MMA-induced decrease of NOS activity and amylase release showed dose-dependent pattern. The data on the time course of CCK-OP-induced citrulline formation and CGMP rise indicate that NOS and guanylate cyclase were activated by treatment of CCK-OP. However, the mechanism of agonist-stimulated guanylate cyclase activation in acinar cells remains unknown. Therefore, activation of NOS is one of the early events in receptor-mediated cascade of reactions in pancreatic acinar cells and NO, not completely, but partially mediate pancreatic enzyme exocrine secretion.

• 한국생물공학회:학술대회논문집
• /
• 2005.10a
• /
• pp.353-353
• /
• 2005

• Journal of the Society of Cosmetic Scientists of Korea
• /
• v.31 no.1 s.49
• /
• pp.1-11
• /
• 2005

The changes of cosmetic industry regulation in the leading countries, such as E.C., America, Japan, initiated our research to suggest the direction of our cosmetics regulation. These countries are strengthening the post-monitoring system for the safety and cosmetic industry development. We propose the agenda for the development of the industry; the extension of cosmetics range, deregulation of the advertisement, implementation of the ingredient labelling, introduction of the product expiring date. Ultimately. it is necessary to introduce and extend current CGMP to enhance the company responsibility and to reinforce the post-monitoring.

• The Journal of the Institute of Internet, Broadcasting and Communication
• /
• v.21 no.1
• /
• pp.149-162
• /
• 2021

This paper established a new smart factory based on manufacturing data for an introductory company focusing on the personalized cosmetics manufacturing industry. We build on an example of a system that collects, manages, and analyzes documents and data that were previously managed by CGMP-based analog for data-driven use. To this end, we have established a system that can collect all data in real time at the production site by introducing artificial intelligence smart factory platform LINK5 MOS and POP system, collecting PLC data, and introducing monitoring system and pin board. It also aims to create a new business cluster space based on this project.

• Proceedings of the Korean Society of Plant Biotechnology Conference
• /
• 2002.04a
• /
• pp.27-31
• /
• 2002

Samyang Genex succeeded in commercialization of anticancer agent-paclitaxel by plant cell culture technology. The core technology of Samyang Genex relating paclitaxel production includes cell line development, cell line preservation, cell culture, scale-up technology, and purification technology. On the basis of the research, Samyang Genex built the factory operated by CGMP (current good manufacturing practice). The $paclitaxel-Genexol^{TM}$ is commercially available in Korea, and it will be launched to world market including USA after approval US FDA.

• Proceedings of the Korean Society of Plant Biotechnology Conference
• /
• 2002.04b
• /
• pp.27-31
• /
• 2002

Samyang Genex succeeded in commercialization of anticancer agent-paclitaxel by plant cell culture technology. The core technology of Samyang Genex relating paclitaxel production includes cell line development, cell line preservation, cell culture, scale-up technology, and purification technology. On the basis of the research, Samyang Genex built the factory operated by CGMP (current good manufacturing practice). The $paclitaxel-Cenexol^{TH}-is$ commercially available in Korea, and it will be launched to world market including USA after approval of US FDA.

• Journal of Plant Biotechnology
• /
• v.29 no.1
• /
• pp.59-62
• /
• 2002

Samyang Genex succeeded in commercialization of anticancer agent-paclitaxel by plant cell culture technology. The core technology of Samyang Genex relating paclitaxel production includes cell line development, cell line preservation, cell culture, scale-up technology, and purification technology. On the basis of the research, Samyang Genex built the factory operated by CGMP (current good manufacturing practice). The paclitaxel-Genexol$^{TM}$-is commercially available in Korea, and it will be launched to world market including USA after approval of US FDA.

• Biomolecules & Therapeutics
• /
• v.3 no.2
• /
• pp.149-153
• /
• 1995

Nitric oxide (NO) has been regarded as one of the neurotransmitters of nonadrenergic, noncholinergic (NANC) nerve stimulation in rabbit corpus cavernosum, rat gastric fundus and human intestine. PIANO (photo-induced adequate nitric oxide) is a very useful tool to investige the role of NO in various smooth muscles where NO is a mediator. The present study was undertaken to compare the physiological responses of the rat gastric smooth muscle in response to NANC nerve stimulation and to PIANO. Photolysis of L-NAME, D-NAME and streptozotocin (572) by UV light in the bathing medium caused relaxation of rat gastric fungus that contracted with carbachol, but was resistant to tetrodotoxin (TTX, 1 $\mu$M). Electrical stimulation (20 V, 2~32 Hz, 0.2 msec, 10s) of the gastric fundus, in the presence of atropine and guanethidine, induced frequency-dependent, TTX-sensitive relaxation. Sodium nitroprusside (1 nM-10 $\mu$M), a NO donor, mimicked the relaxations observed after NANC-stimulation or PIANO. Furthermore, PIANO caused UV light exposure time-dependent increase of CGMP in rat gastric fungus strips. These results provide another evidence indirectly that NO is one of the mediators of the NANC inhibitory nerve stimulation in the rat gastric fundus.

• The Korean Society of Law and Medicine
• /
• v.15 no.2
• /
• pp.63-89
• /
• 2014

In 1976, the Dalkon Shield-intrauterine device injured several thousand women in U.S.A. which caused the changes of medical deivce regulation. The Medical Device Regulation Act or Medical Device Amendments of 1976 (MDA) was introduce. As part of the process of regulating medical devices, the MDA divides medical devices into three categories. The class II, and III devices which have moderate harm or more can use the section 510 (k), premarket notification process if the manufacturer can establish that its device is "substantially equivalent" to a device that was marketed before 1976. In 21 U.S.C. ${\S}$ 360k(a), MDA introduced a provision which expressly preempts competing state laws or regulations. After that, the judicial debates had began over the proper interpretation and application of Section 360(k) In February 2008, the U.S. Supreme Court ruled in Riegel v. Medtronic that manufacturer approved by the Food and Drug Administration (FDA)'s pre-market approval process are preempted from liability, even when the devices have defective design or lack of labeling. But the Supreme Court ruled in Medtronic Inc. v. Lora Lohr that the manufactures which use the section 510 (k) process cannot be preempted and in Bausch v. Stryker Corp. that manufactures which violated the CGMP standard are also liable to the damage of patient at the state courts. In 2009, the Supreme Court ruled in Wyeth v. Levine that patients harmed by prescription drugs can claim damages in state courts. This may cause a double standard between prescription drugs and medical devices. FDA Preemption is the legal theory in the United States that exempts product manufacturers from tort claims regarding Food and Drug Administration approved products. FDA Preemption has been a highly contentious issue. In general, consumer groups are against it while the FDA and pharmaceutical manufacturers are in favor of it. This issues also influences the theory of product liability of U.S.A. Complete immunity preemption is an issue need to be more declared.